The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Les traitements ciblés ont profondément modifié la prise en charge des patients atteints de polyarthrite rhumatoïde (PR). L’abatacept fait partie de ces nouvelles thérapeutiques qui reposent sur une connaissance accrue de l’immunopathologie articulaire. En bloquant l’interaction entre cellules présentatrices d’antigène et lymphocytes T, l’abatacept diminue l’activation lymphocytaire T et favoriserait...
The introduction of targeted treatments has radically changed the management of patients with rheumatoid arthritis (RA). Abatacept is among these new treatments emerging from recent insights into joint immunopathology. Abatacept blocks the interaction between antigen-presenting cells and T-cells, thereby diminishing T-cell activation and possibly improving overall cell regulation. In RA patients,...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.